Blood
Audio Summaries

Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study

Aug 6, 2026

The authors aimed to evaluate the long-term efficacy and safety of talquetamab, a bispecific antibody targeting GPRC5D, in patients with relapsed/refractory multiple myeloma over a three-year follow-up period from the MonumenTAL-1 study. Results indicated an overall response rate of 67-74% and a median overall survival of 34.0 months, with a manageable safety profile characterized by common adverse events such as cytokine release syndrome and taste changes. The findings suggest that talquetamab provides durable responses and a favorable safety profile compared to existing therapies.

A quantitative definition of the clinical manifestations of GATA2 deficiency in adults

Aug 6, 2026

The authors aimed to quantitatively define the clinical manifestations of GATA2 deficiency in adults to aid in the curation of germline variants associated with the condition. By analyzing phenotype data from 339 individuals with GATA2 deficiency and comparing it to control data, they identified specific combinations of phenotypes that characterize the condition. This definition will help establish standardized criteria for variant curation in clinical laboratories globally.

How I treat autoimmune neutropenia in adults

Aug 6, 2026

The authors aim to address the management of autoimmune neutropenia (AiN) in adults, a rare condition that is often chronic and typically asymptomatic despite low neutrophil counts. They highlight the challenges in treatment due to the variable clinical presentation and the unclear mechanisms behind neutrophil destruction, suggesting that observation and supportive care are usually preferred. The paper discusses potential treatment strategies, including boosting neutrophil production and targeting immune-mediated destruction, while emphasizing the need for collaborative efforts to improve treatment approaches for this condition.

Expansion of functional human long-term HSCs through restraining excessive cell cycle activation

Aug 6, 2026

The authors investigate how to expand functional human long-term hematopoietic stem cells (HSCs) ex vivo while preserving their self-renewal and multilineage potential, which are often compromised in current culture systems. By employing single-cell multiome sequencing, they identify molecular mechanisms behind the functional decline and myeloid bias of cultured HSCs, and develop a niche-mimetic culture system that effectively maintains HSC characteristics and enhances their expansion. This study provides insights into the preservation of stemness in HSCs during culture, addressing a critical barrier to their clinical application.

DRP1-mediated mitochondrial fragmentation is a druggable vulnerability in multiple myeloma

Aug 4, 2026

The authors investigate the role of mitochondrial dynamics, specifically the fission protein DRP1, in multiple myeloma (MM) and its potential as a therapeutic target. They find that MM cells exhibit excessive mitochondrial fragmentation, which is linked to treatment resistance and poor patient outcomes. By inhibiting DRP1, either genetically or pharmacologically, they demonstrate significant anti-myeloma effects, suggesting that targeting mitochondrial fission could be a promising strategy for treating relapsed or refractory MM.

Boosting anti-leukemia cytotoxicity of CD4 and CD8 T cells through combined inhibition of MEK and HDAC

Aug 4, 2026

This study investigates whether the combined inhibition of MEK and HDAC can enhance the anti-leukemia cytotoxicity of CD4 and CD8 T cells in acute myeloid leukemia (AML). The authors found that the drug combination of trametinib and quisinostat (TQ) significantly inhibited the growth of various AML cell types and improved T cell function, leading to enhanced leukemia recognition and killing. Their findings suggest that TQ not only targets AML cells but also reprograms T cells to overcome dysfunction, resulting in effective AML clearance.

Recipient Endothelial IRF1 mediates IFNγ-driven tissue tolerance in mouse models of acute Graft-versus-Host Disease

Aug 4, 2026

The authors investigate how recipient endothelial cells (ECs) influence the pathology of acute graft-versus-host disease (GVHD) following allogeneic hematopoietic cell transplantation (allo-HCT), specifically focusing on the role of interferon-γ (IFNγ) and the transcription factor IRF1. Their findings reveal that IFNγ-IRF1 signaling in lymphatic ECs is crucial for mediating tissue tolerance and regulating donor T cell responses, suggesting that a balanced activation of this pathway is essential for improving post-transplant outcomes and reducing GVHD severity.

Functional restoration of immune defects in STAT1 gain-of-function disease following stem cell gene editing

Aug 4, 2026

The authors investigate whether gene editing can serve as a curative alternative to allogeneic hematopoietic stem cell transplantation for patients with STAT1 gain-of-function disease, which causes severe immune deficiencies. They demonstrate that adenine base editing can efficiently correct the pathogenic STAT1 mutation in patient-derived T cells and hematopoietic stem cells, restoring immune function and maintaining long-term engraftment in vivo. This study highlights the potential of gene editing to address dominant gain-of-function mutations in immunodeficiencies and other genetic disorders.

1F10, a λ Light Chain Amyloid-Specific Monoclonal Antibody for Targeted Therapy of AL Amyloidosis

Jul 29, 2026

The authors aim to develop a targeted therapy for AL amyloidosis by creating 1F10, a high-affinity monoclonal antibody specifically designed to bind to lambda light chain (LC) amyloid fibrils. Unlike previous therapies that failed due to insufficient binding affinity, 1F10 demonstrates superior binding and enhances the clearance of amyloid fibrils in vitro and in vivo, positioning it as a promising immunotherapeutic candidate for patients affected by this condition.

A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models

Jul 29, 2026

The authors investigate the efficacy of a novel ribonuclease-targeting chimera (MYC-RiboTAC) designed to degrade MYC mRNA in multiple myeloma (MM) cells, addressing the challenge of targeting the MYC oncogene. Their findings demonstrate that MYC-RiboTAC effectively reduces MYC expression, inhibits MYC-driven transcriptional programs, and shows potent anti-MM activity, particularly in combination with existing therapies, suggesting its potential as a precision treatment for cancers driven by "undruggable" proteins like MYC.